-
-
-
-
-
-
-
Tango Therapeutics (TNGX) Reiterated at Buy by Stifel After Pipeline Updates
-
-
-
-
-
-
-
Tango Therapeutics Inc. (TNGX) PT Raised to $12 at Guggenheim
-
-
-
-
-
-
-
Tango Therapeutics (TNGX) Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lun
-
-
-
-
-
-
-
Tango Therapeutics, Inc (TNGX) Reports Positive TNG462 Clinical Data, Provides Update on PRMT5 Development Program
-
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

